CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Stopping Tenofovir Disoproxil Fumarate (TDF) treatment after long term virologic suppression in HBeAg-negative CHB: Week 48 interim results from an ongoing randomized, controlled trial („FINITE CHB“)
DOI 10.1055/s-0035-1559167
Bibliografische Angaben
Nachweis in CareLit
Autor:innenT Berg, K Simon, S Mauss, E Schott, R Heyne, D Klass, C Eisenbach, T Welzel, R Zachoval, G Felten, J Schulze-zur-Wiesch, M Cornberg, E Martins, L Gallo, T Warger, J Petersen
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background and Aims: Long-term effective NUC therapy may lead to partial restoration of HBV-specific T cell functions. Stopping therapy in HBV-DNA suppressed HBeAg-negative patients may lead to initial viral rebound and hepatic flare followed by HBsAg clearance. We investigated HBsAg kinetics after controlled stopping of long-term TDF therapy. Methods: Subjects on effective TDF therapy for at least 4 years were rand…
Zitieren
Zitierempfehlung
T Berg, K Simon, S Mauss, E Schott, R Heyne, D Klass, C Eisenbach, T Welzel, R Zachoval, G Felten, J Schulze-zur-Wiesch, M Cornberg, E Martins, L Gallo, T Warger, J Petersen (2015) Stopping Tenofovir Disoproxil Fumarate (TDF) treatment after long term virologic suppression in HBeAg-negative CHB: Week 48 interim results from an ongoing randomized, controlled trial („FINITE CHB“). Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0035-1559167
Mit CareLit weiterarbeiten